XML 40 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Revenues:        
Revenue under collaborative research and development arrangements $ 4,335,236 $ 3,107,781 $ 8,580,807 $ 4,543,508
Revenue under collaborative research and development arrangements with affiliated entity 166,667 137,500 279,167 254,464
Grants and miscellaneous revenue 784,775 556,381 1,593,341 1,361,333
Total revenues 5,286,678 3,801,662 10,453,315 6,159,305
Operating expenses:        
Research and development 16,688,511 9,607,281 26,114,831 17,832,761
General and administrative 4,718,260 4,347,327 8,826,188 8,479,545
Gain on sale of assets (1,000,000) 0 (1,000,000) 0
Total operating expenses 20,406,771 13,954,608 33,941,019 26,312,306
Loss from operations (15,120,093) (10,152,946) (23,487,704) (20,153,001)
Other income (expense):        
Interest and other income, net 146,332 68,999 284,608 121,075
Change in fair value of common stock warrants (49,773) 824,390 (51,000) 318,464
Gain (loss) on investment in affiliated entity 8,861,145 (1,458,160) 6,508,836 (1,835,123)
Net loss (6,162,389) (10,717,717) (16,745,260) (21,548,585)
Net (gain) loss attributable to non-controlling interest (85,861) 6,443 (84,769) 15,851
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (6,248,250) $ (10,711,274) $ (16,830,029) $ (21,532,734)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders:        
Basic (in USD per share) $ (0.09) $ (0.18) $ (0.26) $ (0.37)
Diluted (in USD per share) $ (0.09) $ (0.19) $ (0.27) $ (0.38)
Weighted average number of common shares outstanding used in per share calculations:        
Basic (in shares) 67,655,975 60,232,498 64,198,528 57,722,938
Diluted (in shares) 67,838,738 60,474,859 64,376,523 57,976,455